Nisa Investment Advisors LLC Has $150,000 Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Nisa Investment Advisors LLC raised its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 115.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,430 shares of the company’s stock after buying an additional 1,300 shares during the period. Nisa Investment Advisors LLC’s holdings in Amphastar Pharmaceuticals were worth $150,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in AMPH. BlackRock Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 1.1% during the third quarter. BlackRock Inc. now owns 7,147,813 shares of the company’s stock worth $200,854,000 after purchasing an additional 75,616 shares during the period. Federated Hermes Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 0.7% during the first quarter. Federated Hermes Inc. now owns 3,487,430 shares of the company’s stock worth $125,199,000 after purchasing an additional 23,095 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 1.8% during the third quarter. Vanguard Group Inc. now owns 2,606,162 shares of the company’s stock worth $73,234,000 after purchasing an additional 45,385 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Amphastar Pharmaceuticals by 2.7% during the first quarter. Dimensional Fund Advisors LP now owns 1,917,571 shares of the company’s stock worth $71,909,000 after purchasing an additional 51,027 shares during the period. Finally, State Street Corp lifted its holdings in shares of Amphastar Pharmaceuticals by 16.6% during the second quarter. State Street Corp now owns 1,540,846 shares of the company’s stock worth $53,606,000 after purchasing an additional 218,895 shares during the period. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ AMPH opened at $40.01 on Friday. Amphastar Pharmaceuticals, Inc. has a twelve month low of $35.62 and a twelve month high of $67.66. The company has a quick ratio of 1.70, a current ratio of 2.17 and a debt-to-equity ratio of 0.92. The company has a market capitalization of $1.96 billion, a PE ratio of 15.51, a P/E/G ratio of 0.96 and a beta of 0.84. The firm has a fifty day simple moving average of $46.27 and a 200 day simple moving average of $51.14.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Wednesday, February 28th. The company reported $0.81 earnings per share for the quarter, missing the consensus estimate of $0.84 by ($0.03). Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%. The company had revenue of $178.11 million during the quarter, compared to the consensus estimate of $174.90 million. On average, sell-side analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.42 EPS for the current year.

Analyst Ratings Changes

AMPH has been the topic of a number of recent research reports. StockNews.com lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. JPMorgan Chase & Co. started coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They set an “overweight” rating and a $60.00 target price for the company. Finally, Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, April 10th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $66.00.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Michael A. Zasloff sold 12,500 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total value of $589,750.00. Following the completion of the sale, the director now directly owns 21,326 shares of the company’s stock, valued at $1,006,160.68. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director Michael A. Zasloff sold 12,500 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total transaction of $589,750.00. Following the completion of the sale, the director now directly owns 21,326 shares of the company’s stock, valued at $1,006,160.68. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Floyd F. Petersen sold 500 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $53.10, for a total transaction of $26,550.00. Following the sale, the director now directly owns 80,333 shares of the company’s stock, valued at $4,265,682.30. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 14,000 shares of company stock valued at $660,860. Corporate insiders own 28.40% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.